Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Exclusion Criteria

• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.
• •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
• •A family history of congenital or hereditary immunodeficiency.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
• •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (with the exception of hepatitis B immunoglobulins at birth).
• •Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception of hepatitis B vaccination at birth or at least 30 days before the subject's first study visit).
• •History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B, Streptococcus and Haemophilus influenzae type b disease.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
• •History of any neurological disorders or seizures.
• •Major congenital defects or serious chronic illness.
• •Acute disease at the time of enrolment.
• •Babies for which birth weight is \< 2 kilogram.